{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:42:38Z","timestamp":1793824958107,"version":"4.6.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100019034","name":"Hubei Provincial Central Guidance Local Science and Technology Development Project","doi-asserted-by":"publisher","award":["YDZJSX20231A059"],"award-info":[{"award-number":["YDZJSX20231A059"]}],"id":[{"id":"10.13039\/501100019034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017592","name":"Key Science and Technology Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2023XM022"],"award-info":[{"award-number":["2023XM022"]}],"id":[{"id":"10.13039\/501100017592","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Shanxi Provincial Central Leading Local Science and Technology Development Fund Project"},{"name":"the Four \u201cBatches\u201d Innovation Project of Invigorating Medical through Science and Technology of Shanxi Province"},{"name":"the Shanxi Province Higher Education \u201cBillion Project\u201d Science and Technology Guidance Project","award":["BYJL-024"],"award-info":[{"award-number":["BYJL-024"]}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.eprac.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:17:07Z","timestamp":1750101427000},"page":"1177-1184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of Pituitary Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9900-506X","authenticated-orcid":false,"given":"Zhe","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2025.06.008_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.eprac.2025.06.008_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.eprac.2025.06.008_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.008_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common Terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo Sifiliograficas"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.008_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.008_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ijc.33768","article-title":"Ipilimumab in a real-world population: a prospective Phase IV trial with long-term follow-up","volume":"150","author":"Aamdal","year":"2022","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.008_bib7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102206","article-title":"Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.eprac.2025.06.008_bib9","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.22.02199","article-title":"First-line, fixed-duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: CheckMate 401","volume":"41","author":"Dummer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eprac.2025.06.008_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2022.05.007","article-title":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","volume":"171","author":"Even","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eprac.2025.06.008_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","article-title":"CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eprac.2025.06.008_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2020.06.032","article-title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study","volume":"147","author":"Garassino","year":"2020","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.008_bib13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.008_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00432-024-05981-2","article-title":"Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel","volume":"150","author":"Grote","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.008_bib15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s10147-023-02394-y","article-title":"Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old","volume":"28","author":"Kobayashi","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eprac.2025.06.008_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.008_bib17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10147-020-01693-y","article-title":"Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes","volume":"25","author":"Numakura","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"24","key":"10.1016\/j.eprac.2025.06.008_bib18","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-20-2819","article-title":"Activity and safety of geptanolimab (GB226) for patients with unresectable, recurrent, or metastatic alveolar soft Part Sarcoma: a phase II, single-arm study","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.008_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.008_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.008_bib21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2025.06.008_bib22","article-title":"Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol","volume":"39","author":"Verkerk","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.008_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","author":"Yamazaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.008_bib24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/1346-8138.15388","article-title":"Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: a postmarketing surveillance","volume":"47","author":"Yamazaki","year":"2020","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.008_bib25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/1346-8138.17002","article-title":"Long-term follow-up results from KEYNOTE-041: phase 1b study of pembrolizumab in Japanese patients with advanced melanoma","volume":"51","author":"Yokota","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.eprac.2025.06.008_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12967-015-0716-5","article-title":"Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma","volume":"13","author":"Zimmer","year":"2015","journal-title":"J Transl Med"},{"issue":"19","key":"10.1016\/j.eprac.2025.06.008_bib27","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced\/metastatic gastric or gastroesophageal junction cancer","volume":"23","author":"Bang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.008_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC","volume":"18","author":"De Castro","year":"2023","journal-title":"J Thoracic Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.008_bib29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.008_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.eprac.2025.06.008_bib31","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-Term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2012positive, advanced non\u2012small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.008_bib32","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10111","key":"10.1016\/j.eprac.2025.06.008_bib33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"10336","key":"10.1016\/j.eprac.2025.06.008_bib34","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.008_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000529636","article-title":"Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial","volume":"12","author":"Merle","year":"2023","journal-title":"Liver Cancer"},{"issue":"10183","key":"10.1016\/j.eprac.2025.06.008_bib36","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.008_bib37","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10379","key":"10.1016\/j.eprac.2025.06.008_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.008_bib39","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.eprac.2025.06.008_bib40","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.008_bib41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10142","key":"10.1016\/j.eprac.2025.06.008_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.008_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.008_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Related Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.008_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.008_bib46","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"44","key":"10.1016\/j.eprac.2025.06.008_bib47","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.008_bib48","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.3390\/jcm12103468","article-title":"Progress and challenges of immune checkpoint inhibitor-induced hypophysitis","volume":"12","author":"Chen","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.008_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Exp Rev Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.06.008_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"issue":"230","key":"10.1016\/j.eprac.2025.06.008_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"36","key":"10.1016\/j.eprac.2025.06.008_bib52","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2500922X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2500922X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:18:48Z","timestamp":1778944728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2500922X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1530891X2500922X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.06.008","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Pituitary Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}